Dyadic (DYAI) Faces Bid-Price Nasdaq Warning; 180-Day Cure Period
Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).
Rhea-AI Filing Summary
Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).
The notice does not immediately affect DYAI’s listing. The company has 180 calendar days—until 13-Jan-2026—to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive trading days. If the requirement is unmet, Dyadic may qualify for a second 180-day grace period, provided it satisfies all initial listing standards other than bid price and formally notifies Nasdaq of its remediation plan. Failure to cure could result in delisting, with the option to appeal.
Management “intends to actively monitor” share price and explore alternatives to resolve the deficiency. The filing also reminds investors that the company remains out of compliance with the $35 million Market Value of Listed Securities rule (Rule 5550(b)(2)); that separate deficiency must be remedied by 20-Dec-2025. Either unresolved deficiency can independently trigger delisting.
Positive
- 180-day grace period gives Dyadic time to regain compliance before any listing penalty.
Negative
- Bid-price deficiency adds to existing MVLS shortfall, heightening delisting probability.
- Company provided no concrete corrective actions, leaving uncertainty around compliance strategy.
Insights
TL;DR: Dual Nasdaq deficiencies increase delisting risk; timeline gives Dyadic limited room to act.
The bid-price notice compounds Dyadic’s existing MVLS shortfall and signals heightened listing risk. Although the 180-day window is standard, the coinciding Dec-2025 MVLS deadline leaves only a narrow margin for simultaneous remediation. The share price’s sub-$1 level also restricts capital-raising flexibility, potentially tightening liquidity. Investors should watch for reverse-split proposals, strategic updates, or partnerships aimed at both value creation and price support. Until tangible corrective steps emerge, the filing skews negative for valuation and liquidity perceptions.
TL;DR: Governance procedures intact, but cumulative compliance gaps pose credibility risk.
The company followed disclosure rules promptly, which is positive from a governance standpoint. However, serial rule violations undermine board credibility and could affect institutional investor confidence. The filing outlines potential appeals, yet success rates are modest unless operational metrics improve. Management’s plan to “evaluate available options” lacks specificity, suggesting no ready remedy. Governance best practices would call for transparent action plans—including possible reverse split thresholds, cost controls or asset monetisation—well before the grace periods expire.
8-K Event Classification
FAQ
Why did Dyadic International (DYAI) receive a Nasdaq deficiency notice?
What is Dyadic’s deadline to regain the $1 bid price compliance?
What happens if Dyadic fails to meet the bid price requirement by the deadline?
What other Nasdaq rule is Dyadic currently violating?
What steps does Dyadic plan to take to regain compliance?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
(a)
On July 17, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until January 13, 2026 (the “Compliance Date”), to regain compliance with the minimum bid price requirement by having the Company’s bid price close at $1 per share or more for a minimum of 10 consecutive business days before the Compliance Date (subject to the Staff’s discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H)). If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance, provided that on the Compliance Date the Company meets the applicable market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on the Nasdaq Capital Market (except the bid price requirement) based on the Company’s most recent public filings and market information and notifies Nasdaq of its intent to cure this deficiency. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company’s common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful.
The Company intends to actively monitor the bid price of its common stock between now and the Compliance Date and, as appropriate, plans to evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.
As previously disclosed, the Company also remains out of compliance with the minimum Market Value of Listed Securities (“MVLS”) of $35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2), and has until December 20, 2025 to regain compliance with such requirement. The bid price deficiency discussed in the Notice is a separate and unrelated deficiency, and either deficiency, if not cured by the applicable deadline, could be a basis for the delisting of the Company’s common stock.
Safe Harbor Regarding Forward-Looking Statements
This current report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, including those regarding the Company’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, including its plan to regain compliance with Nasdaq Listing Rule 5550(a)(2). Forward-looking statements involve many risks, uncertainties or other factors beyond the Company’s control. These factors include, but are not limited to, the following: (i) the Company’s history of net losses; (ii) the Company’s ability to maintain compliance with other Nasdaq continued listing standards and rules, including the minimum MVLS rule; (iii) the Company’s capital needs; and (iv) other factors impacting the Company’s business, results of operations and stock price, including market and regulatory acceptance of the Company’s microbial protein production platforms and other technologies, failure to commercialize the Company’s microbial protein production platforms or the Company’s other technologies, competition, including from alternative technologies, the results of nonclinical studies and clinical trials, changes in global economic and financial conditions, the Company’s reliance on information technology, the Company’s dependence on third parties, government regulations and environmental, social and governance issues, and intellectual property risks. For a more complete description of the risks that could cause the Company’s actual results to differ from the Company’s current expectations, please see the section entitled “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), as such factors may be updated from time to time in the Company’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, the Company assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this Current Report on Form 8-K to conform these statements to actual results or to changes in the Company’s expectations.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 23, 2025
| Dyadic International, Inc. | ||
| By: | /s/ Ping Rawson | |
| Name: | Ping Rawson | |
| Title: | Chief Financial Officer | |